C Renner
Spotlight on pomalidomide: could less be more?
Zander T, Aebi S, Pabst T, Renner C, Driessen C. Spotlight on pomalidomide: could less be more?. Leukemia 2017; 31:1987-1989.
May 22, 2017Spotlight on pomalidomide: could less be more?
May 22, 2017Leukemia 2017; 31:1987-1989
Zander T, Aebi S, Pabst T, Renner C, Driessen Christoph
Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma
Schuberth P, Renner C, Fox B, Bifulco C, Tinguely M, Thiel M, Held G, Mischo A, Haile S, Haley D, Gautschi F, Wadle A, Jensen S, Jakka G, Petrausch U. Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma. Gene Ther 2012
Jun 28, 2012Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma
Jun 28, 2012Gene Ther 2012
Schuberth P C, Renner C, Fox B A, Bifulco C B, Tinguely M, Thiel M, Held G, Mischo A, Haile Sarah, Haley D, Gautschi F, Wadle A, Jensen S M, Jakka G, Petrausch U
Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases
Samaras P, Pestalozzi B, Knuth A, Renner C, Feilchenfeldt J, Heinrich S, Stenner-Liewen F, Haile S, Breitenstein S, Clavien P. Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases. Ann Surg Oncol 2011; 18:1924-31.
Jan 5, 2011Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases
Jan 5, 2011Ann Surg Oncol 2011; 18:1924-31
Samaras Panagiotis, Pestalozzi B C, Knuth A, Renner C, Feilchenfeldt J, Heinrich S, Stenner-Liewen F, Haile Sarah, Breitenstein S, Clavien P A
Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy
Petrausch U, Renner C, Mischo A, Hany T, Knuth A, Soyka J, Veit-Haibach P, Haile S, Samaras P, Schäefer N. Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy. Ann Oncol 2010; 21:1694-8.
Feb 5, 2010Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy
Feb 5, 2010Ann Oncol 2010; 21:1694-8
Petrausch U, Renner C, Mischo A, Hany T F, Knuth A, Soyka J D, Veit-Haibach P, Haile Sarah, Samaras P, Schäefer N G
MAGE-C1/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcome
Tinguely M, Knuth A, Moch H, Probst-Hensch N, Renner C, Maurer R, Dommann-Scherrer C, Schmid U, Bittermann A, Cogliatti S, Curioni Fontecedro A, Rousson V, Korol D, Lopes B, Knights A, Jenni B, Zippelius A. MAGE-C1/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcome. Cancer science 2008; 99:720-5.
Apr 1, 2008MAGE-C1/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcome
Apr 1, 2008Cancer science 2008; 99:720-5
Tinguely M, Knuth A, Moch H, Probst-Hensch N M, Renner C, Maurer R, Dommann-Scherrer C, Schmid U, Bittermann A G, Cogliatti Sergio B., Curioni Fontecedro A, Rousson V, Korol D, Lopes B, Knights A, Jenni B, Zippelius A